Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biotech Vaneck ETF (BBH)

Biotech Vaneck ETF (BBH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Van Eck Associates
  • Assets Under Management 492,648,000
  • Shares Outstanding, K 2,772
  • 60-Month Beta 0.90
Trade BBH with:
  • Price/Earnings ttm 26.71
  • Annual Dividend & Yield 0.61
  • Most Recent Dividend 0.608
  • Management Fee 0.35%
  • Sectors:

    ETFs - Biotech

Options Overview

Details
  • Implied Volatility 28.97%
  • Historical Volatility 24.35%
  • IV Percentile 99%
  • IV Rank 0.00%
  • IV High 30.70% on 02/26/21
  • IV Low 28.97% on 03/01/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio 0.00
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
171.18 +0.11%
on 03/03/21
197.28 -13.13%
on 02/16/21
-16.39 (-8.73%)
since 02/03/21
3-Month
166.87 +2.70%
on 01/04/21
197.28 -13.13%
on 02/16/21
+0.49 (+0.29%)
since 12/03/20
52-Week
112.03 +52.97%
on 03/23/20
197.28 -13.13%
on 02/16/21
+36.36 (+26.93%)
since 03/03/20

Most Recent Stories

More News
How Will Biotech ETFs React to These Q4 Earnings Releases?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.

BIIB : 266.60 (-1.20%)
ALXN : 148.19 (-1.45%)
GILD : 62.75 (-0.41%)
AMGN : 223.94 (-0.78%)
IBB : 150.77 (-3.58%)
XBI : 139.94 (-4.71%)
BBH : 171.37 (-3.54%)
Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

MRNA : 131.22 (-10.62%)
NVAX : 183.61 (-10.86%)
IBB : 150.77 (-3.58%)
XBI : 139.94 (-4.71%)
BBH : 171.37 (-3.54%)
GERM : 35.20 (-6.63%)
Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?

Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.

MRNA : 131.22 (-10.62%)
IBB : 150.77 (-3.58%)
XBI : 139.94 (-4.71%)
BBH : 171.37 (-3.54%)
BTEC : 59.51 (-5.11%)
GERM : 35.20 (-6.63%)
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

PFE : 34.39 (+2.63%)
MRNA : 131.22 (-10.62%)
LLY : 202.00 (-1.05%)
IBB : 150.77 (-3.58%)
CNCR : 30.58 (-3.29%)
XBI : 139.94 (-4.71%)
BBH : 171.37 (-3.54%)
FBT : 161.76 (-3.36%)
SBIO : 52.18 (-4.87%)
PBE : 71.02 (-4.51%)
BTEC : 59.51 (-5.11%)
ARKG : 90.33 (-5.87%)
BNTX : 97.25 (-7.36%)
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

ALXN : 148.19 (-1.45%)
AZN : 47.16 (-1.19%)
PPH : 67.22 (-0.91%)
BBH : 171.37 (-3.54%)
FBT : 161.76 (-3.36%)
PJP : 75.59 (-1.41%)
PBE : 71.02 (-4.51%)
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens

Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.

IBB : 150.77 (-3.58%)
XBI : 139.94 (-4.71%)
BBH : 171.37 (-3.54%)
BTEC : 59.51 (-5.11%)
IDNA : 44.50 (-5.26%)
GERM : 35.20 (-6.63%)
How Will Biotech ETFs React to These Q3 Earnings Release?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.

BIIB : 266.60 (-1.20%)
ALXN : 148.19 (-1.45%)
GILD : 62.75 (-0.41%)
AMGN : 223.94 (-0.78%)
IBB : 150.77 (-3.58%)
XBI : 139.94 (-4.71%)
BBH : 171.37 (-3.54%)
Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain

Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.

IBB : 150.77 (-3.58%)
XBI : 139.94 (-4.71%)
BBH : 171.37 (-3.54%)
BTEC : 59.51 (-5.11%)
IDNA : 44.50 (-5.26%)
GERM : 35.20 (-6.63%)
Biotech ETFs to Shine on Coronavirus Antibodies Progress

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

IBB : 150.77 (-3.58%)
XBI : 139.94 (-4.71%)
BBH : 171.37 (-3.54%)
PBE : 71.02 (-4.51%)
ARKG : 90.33 (-5.87%)
Biotech ETFs to Gain on Trump's COVID-19 Treatment Protocol

The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.

IBB : 150.77 (-3.58%)
XBI : 139.94 (-4.71%)
BBH : 171.37 (-3.54%)
PBE : 71.02 (-4.51%)
ARKG : 90.33 (-5.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Fund Summary

The VanEck Vectors Biotech ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index, which is intended to track the overall performance of companies involved in the development and production, marketing and sales of...

See More

Top 10 Holdings

Key Turning Points

3rd Resistance Point 180.42
2nd Resistance Point 178.54
1st Resistance Point 174.95
Last Price 171.37
1st Support Level 169.48
2nd Support Level 167.60
3rd Support Level 164.01

See More

52-Week High 197.28
Last Price 171.37
Fibonacci 61.8% 164.71
Fibonacci 50% 154.65
Fibonacci 38.2% 144.60
52-Week Low 112.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar